JTX-8064-101 Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with

NCT04669899

Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Associated Conditions

Multiple Myeloma

Principal Investigator

Guru Sonpavde

Sponsor

Jounce Therapeutics, Inc

A medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening the symptoms or the participants have declined approved treatments. This research study, involves two experimental drugs called JTX-8064 (also known as “study drug”) and JTX-4014. JTX-8064 and JTX-4014 are investigational drugs.